WIN 54954 is an orally active and broad-spectrum antipicornavirus agent. WIN 54954 is effectiveness against human rhinovirus, echovirus 9 and enterovirus infections. In Vitro WIN 54954 reduces plaque formation of 50 of 52 rhinovirus serotypes (MICs ranges from 0.007 to 2.2 μg/mL).\nWIN 54954 inhibits 15 commonly isolated enteroviruses, with an EC 80 of 0.06 μg/mL. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo WIN 54954 (2-100 mg/kg; p.o.) protects 50% of the mice from developing paralysis following infection with coxsackievirus A-9 and echovirus-9 at the dose of 2 and 100 mg/kg, respectively . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid